|Bid||85.88 x 3100|
|Ask||85.96 x 900|
|Day's Range||82.44 - 85.99|
|52 Week Range||75.52 - 110.37|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||39.27|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||106.38|
The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.
Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.
WILMINGTON, Del., Jun 12, 2021--Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference